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(RECEIVED FOR PUBLICATION SEPTEMBER 9, 1960) 
Abstract: 
Human oxalated plasma stored at 4°C. until the prothrombin time is 
increased beyond 60 sec. is a reliable medium for assaying labile factor 
(factor V) because its response to added labile factor corresponds 
quantitatively to that of plasma from patients with congenital deficiency of 
this factor. Such an agreement is not obtained with plasma stored at 37°C. 
The stability of labile factor is closely associated with ionized calcium. The 
addition of thrombin to fresh oxalated plasma causes an apparent 
hyperactivity of labile factor, but this is completely removed by adsorption 
with Ca3(PO)2. Oxalated plasma when adsorbed with Ca3(PO4)2 before 
treatment with thrombin does not develop this adventitious activity, nor does 
it occur in stored plasma treated with thrombin. The seemingly high labile 
factor activity in serum can be explained by the activation of this factor which 
is independent of labile factor but acts synergistically with it. The true labile 
factor concentration can be determined only after the accelerator is removed 
by adsorption with Ca3(PO4)2. A close agreement between the consumption of 
prothrombin and the loss of labile factor during clotting is observed.  
The discovery in 1943 of a new clotting factor now commonly known as labile 
factor or factor V, which was not recognized in the classical theory of blood 
coagulation formulated by Morawitz in 1904, initiated a radically new 
approach to the study of coagulation mechanisms and the haemorrhagic 
diseases. Owren (1947a) described the first case in which a bleeding state 
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was caused by lack of a factor which appeared to be similar or identical with 
the one which is decreased when oxalated human plasma is stored at 4°C. On 
the assumption that the prolonged prothrombin time of such stored plasma is 
caused specifically by a loss of labile factor, a method of assay using a stored 
human plasma as the medium was developed by Quick and Stefanini (1948). 
With this procedure, it was shown that human blood contains a much lower 
concentration of labile factor than the blood of the common laboratory 
animals. Since there had been no opportunity to compare stored plasma 
directly with that from a patient with congenital deficiency of labile factor, the 
unequivocal reliability of the assay method could not be established. With the 
availability recently of blood from three siblings having strikingly low 
concentrations of labile factor, such a comparative study could be made, and 
it prompted a reinvestigation of this clotting factor. 
Material and Methods 
Collection of Blood. — A silicone-coated needle and syringe were used 
and the blood was transferred to test-tubes similarly coated. These were kept 
in an ice bath until used. 
One-stage Prothrombin Time. — The exact procedure as 
previously described (Quick, 1957) was followed. This included using sodium 
oxalate as the anticoagulant, acetone-dehydrated rabbit brain as the 
thromboplastin reagent, and 0.01M CaCl2 for recalcification. A prothrombin 
time of 12 sec. for fresh normal human plasma was mandatory in the control 
for each experiment. 
Adsorption of Plasma to Remove Prothrombin and 
Stable Factor (Factor VII). — One millilitre of a suspension of 
0.012M Ca3(PO4)2 contains the correct amount of adsorbent to remove 
completely the prothrombin and stable factor (factor VII) from 1 ml. of 
oxalated rabbit plasma. The required volume of the suspension is pipetted 
into a test-tube and the Ca3(PO4)2 is packed by centrifugation. The 
supernatant water is poured off, and after the tube is drained the plasma is 
added and mixed with the Ca3(PO4)2. After five minutes the adsorbent is 
removed by high centrifugation. 
Results 
Comparison of Stored Human Plasma with Plasma from 
Subjects Having Congenital Deficiency of Labile 
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Factor.— On adding an equal volume of fresh normal oxalated plasma 
either to plasma from a patient with congenital deficiency of labile factor or to 
stored plasma, a mixture is obtained which has approximately a normal 
prothrombin time (11 -13 sec.) (Table I). No correction is obtained when 
labile-factor- deficient plasma is mixed with stored plasma. On adding fixed 
amounts of deprothrombinized rabbit plasma, which has a high concentration 
of labile factor, to the patient's plasma and to stored plasma, the correction of 
the prothrombin time is quantitatively the same in both types of plasma 
except that, with increasing amounts, a minimum prothrombin time of 8 sec. 
is obtained in stored plasma and 1 1 sec. in the patient's fresh plasma. When 
the patient's plasma is stored for 48 hours in glass at 40 C., a minimum 
prothrombin time of 8+ sec. is then obtained. A probable explanation for this 
will be offered in the discussion. 
Table I 
Comparison Of Plasma From Patients Having Congenital Labile Factor Deficiency With Stored 
Plasma In The Response To Added Labile Factor 
 Prothrombin Time (sec.) 
Patient 1* Patient 2 Stored Plasma 
Undiluted plasma 
Plasma diluted with an equal volume of normal 
plasma 
Plasma diluted with an equal volume of stored 
plasma 
Amount of deprothrombinized rabbit plasma 
added to 0-1 ml. plasma: 
0.001 ml. 
0.005 ml. 
0.01 ml. 
0.02 ml. 
0.05 ml. 
0.05 ml. 
 
53 
 
12 
 
55 
 
 
23 
14 
12 
12 
11.5 
8.5† 
42 
 
13 
 
48 
 
 
20 
15 
11.5 
12 
11.5 
8.5† 
95 
 
11.5 
 
95 
 
 
23 
14 
11 
10 
8 
 
* The basic prothrombin consumption time of Patient 1 was 10.5 sec. When 0.1 ml. of 
deprothrombinized rabbit plasma was added to 1 ml. of the patient's blood before clotting, the 
prothrombin consumption time was 45 sec. 
†After 48 hours' storage in glass. 
 
The results in Table I show that normal plasma stored at 4°C. appears to be 
nearly identical to plasma from patients with congenital labile factor 
deficiency. The ease with which labile factor can be diminished by storage at 
4°C. makes the preparation of plasma suitable for assaying labile factor very 
simple. 
The method of Wolf (1953) for preparing plasma for assaying labile 
factor was found unsatisfactory. He incubates oxalated plasma at 37°C. for 24 
hours. From the results presented in Table II, it is evident that changes other 
than loss of labile factor occur in the plasma, so that the addition of excess 
labile factor does not bring the prothrombin time to normal as it will when 
added to plasma stored at 4°C. 
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Table II 
Comparison Of Human Oxalated Plasmas Stored At 4°C. For 14 Days And At 37°C.  
For 24 Hours In Response To Added Labile Factor 
 Prothrombin Time (sec.) 
Fresh Stored at 4°C 
for 14 Days 
Stored at 37°C 
for 24 Hours 
Deprothrombinized rabbit plasma added  
to 0-1 ml. plasma: 
0 ml. 
0.01 ml. 
0.05 ml. 
 
 
 
12 
12 
11 
 
 
60 
10 
8 
 
 
240 
50 
18 
 
Assay Method for Labile Factor.— Normal oxalated plasma is 
distributed in 5 ml. portions to test-tubes which are placed in a refrigerator 
kept at 4°C. The prothrombin time is determined after seven days, and again 
at several days' intervals, until it has increased to 60 sec. This requires about 
a fortnight. The plasmas are pooled and stored at -20°C.  
The labile factor curve is based on the finding that when 1 vol. of fresh 
human plasma is mixed with 9 vol. of stored plasma, the mixture has a 
prothrombin time which averages about 18 sec. The usual range is 17 to 20 
sec. A plasma giving a correction of 18 sec. is arbitrarily designated as having 
a labile factor concentration of 100, and, since 1 vol. of this plasma is mixed 
with 9 vol. of stored plasma which has a concentration of less than 1%, the 
18 sec. can be regarded as the prothrombin time of a plasma containing 10% 
of labile factor. By means of varying dilutions of stored plasma with fresh, 
values are obtained from which a curve can be constructed correlating the 
prothrombin time with labile factor deficiency (Fig. 1). It will be noted that the 
prothrombin time becomes 12 sec. when 4 vol. of fresh plasma is mixed with 
6 vol. of stored plasma. Fresh plasma contains over twice as much labile 
factor as is required to maintain the prothrombin time at 12 sec.; 
consequently, over half can be lost before the prothrombin time is prolonged. 
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In carrying out the test, the plasma to be assayed is adsorbed with 
Ca3(PO4)2 at 40 C. This removes very little labile factor, but it does take out 
an accelerator which may be present. One-hundedth of a millilitre of the 
adsorbed plasma is mixed with 0.09 ml. of stored human plasma and the 
prothrombin time of the mixture determined. The value in terms of 
percentage of labile factor is read from the chart and multiplied by 10 
because of the dilution.  
The assay method is sensitive to small changes in labile factor even in 
the range before the prothrombin time is affected. This is illustrated by the 
simple experiment of incubating oxalated human plasma for 30 min. at 37°C. 
Owren (1947b) states that no deterioration of factor V occurs in this short 
period, yet when studied by our method (Table III) it is found that the activity 
decreased from 120% to 86%, which is a drop of 28%. 
Concentration of Labile Factor in Various Laboratory 
Animals.— The determination of labile factor in the blood of the common 
laboratory animals is simple because the concentration is much higher than in 
human plasma. One need only determine how much the plasma has to be 
diluted to correct the prothrombin time of stored human plasma to 18 sec., 
which has been set as the normal correction when 1 vol. of fresh human 
plasma is mixed with 9 vol. of stored plasma. In determining the labile factor, 
the animal plasma is diluted with saline in various proportions. To 0.09 ml. of 
stored plasma, 0.01 ml. of the diluted plasma is added and the prothrombin 
time determined. From the prothrombin time obtained, the concentration of 
labile factor is calculated. The outstanding finding is the high concentration of 
labile factor in rabbit plasma and the low level in human plasma (Table IV). 
Table III 
Effect Of Incubating Oxalated Plasma At 37°C. On Labile Factor 
 Prothrombin Time (sec.) Labile 
Factor 
(%) 
Basic Mixed with 9 
vol. of Aged 
Plasma 
Before incubation 
After 30 min. incubation 
After 120 min. incubation 
12 
12 
11 
17 
19 
30 
120 
86 
29 
 
Table IV 
Relative Concentration Of Labile Factor(Factor V) 
In Plasma Of Various Species 
Man Rabbit Dog Cat Cow Sheep 
100 5,000 1,000 350-500 800 300-500 
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Table V 
Effect Of Various Anticoagulants On Prothrombin Time 
And Labile Factor During Storage At 4°C. 
Anticoagulant Time of 
Storage 
(hr.) 
Prothrombin Time 
In Glass In Silicone 
Basic 
(sec.) 
Corrected 
for Labile 
Factor * 
(sec.) 
Mixed 
with 9 
vol. Aged 
Plasma† 
(sec.) 
Basic 
(sec.) 
Corrected 
for Labile 
Factor * 
(sec.) 
Mixed 
with 9 
vol. Aged 
Plasma† 
(sec.) 
Sodium 
oxalate 0.1M 
0 
24 
48 
12 
14 
20 
12 
8.5 
8 
17 
29 
41 
12 
16.5 
23 
12 
12 
12 
17 
26 
36 
Sodium 
citrate 0.1M 
0 
24 
48 
12 
9 
10.5 
12 
8 
8.5 
17 
18 
20 
12 
12 
13 
11 
12 
11 
17 
18 
17.5 
Sodium 
citrate 0.2M 
0 
24 
48 
12 
13 
16 
12 
8.5 
9 
17 
21 
25 
12 
14.5 
17.5 
12 
12 
12 
17.5 
20.5 
24 
None 0 
24 
48 
   12 
12 
12 
11 
11 
11.5 
17 
16.5 
17 
* To 0.09 ml. of the plasma, 0.01 ml. of deprothrombinized rabbit plasma was added. 
†To 0.09 ml. of aged plasma, 0.01 ml. of the plasma studied was added. 
 
Effect of Anticoagulants on Labile Factor in Plasma 
Stored at 4°C.— Three types of plasma were studied: oxalated, citrated, 
and native. The results are recorded in Table V. The decrease of labile factor 
is greatest in oxalated plasma, but it is also fairly rapid when plasma is mixed 
with 0.2M sodium citrate. With 0.1M sodium citrate, the loss of labile factor is 
greatly retarded and in native plasma is almost negligible in the first 48 
hours. The decrease of labile factor is not significantly different in glass or 
silicone-coated containers, but the prothrombin activity as measured by the 
prothrombin time after adding an excess of labile factor is increased in glass 
but remains practically unchanged in silicone. 
Concentration of Labile Factor in Serum.— When human blood 
is clotted in glass, the resulting serum appears to have a higher labile factor 
activity than does the corresponding oxalated plasma as shown in Table VI. 
When the serum is adsorbed with Ca3(PO4)2, this hyperactivity is lost and the 
concentration of labile factor is found actually to be low, suggesting that much 
of this factor is consumed during clotting. If platelet-poor plasma is clotted, 
the resulting serum also shows the apparent hyperactivity, which, after 
adsorption, is lost, but the residual concentration of labile factor is higher 
than in the serum obtained from the clotting of whole blood or platelet-rich 
plasma. 
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Table VI 
Labile Factor Activity in Serum 
Stored oxalated plasma (ml.) 
Serum from normal blood (Serum A)(ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
5.5 
0.08 
0.02 
6.5 
0.09 
0.01 
8.0 
Stored oxalated plasma (ml.) 
Serum A adsorbed with Ca3(PO4)2 (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
20.0 
0.08 
0.02 
23.0 
0.09 
0.01 
29.0 
Stored oxalated plasma (ml.) 
Serum from platelet-poor plasma (Serum B) (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
5.2 
0.08 
0.02 
6.5 
0.09 
0.01 
8.0 
Stored oxalated plasma (ml.) 
Serum B adsorbed with Ca3(PO4)2 (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
12.0 
0.08 
0.02 
13.0 
0.09 
0.01 
16.0 
Stored oxalated plasma (ml.) 
Serum from platelet-rich plasma (Serum C) (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
7.5 
0.08 
0.02 
7.5 
0.09 
0.01 
8.2 
Stored oxalated plasma (ml.) 
Serum C adsorbed with Ca3(PO4)2 (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
18.0 
0.08 
0.02 
21.0 
0.09 
0.01 
25.0 
 
Action of Thrombin on Labile Factor in Oxalated 
Plasma.— When thrombin is added to oxalated plasma, the resulting 
defibrinated product has, like serum, a distinct hyperactivity when tested on 
stored plasma (Table VII),  
Table VII 
Effect Of Thrombin On Labile Factor Activity 
Stored oxalated plasma (ml.) 
Fresh oxalated plasma (Plasma A) (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
12.2 
0.08 
0.02 
13.5 
0.09 
0.01 
17.5 
Stored oxalated plasma (ml.) 
Plasma A treated with thrombin* (Plasma B) (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
9.0 
0.08 
0.02 
10.0 
0.09 
0.01 
11.0 
Stored oxalated plasma (ml.) 
Plasma B adsorbed with Ca3(PO4)2 (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
15.0 
0.08 
0.02 
19.0 
0.09 
0.01 
22.0 
Stored oxalated plasma (ml.) 
Plasma A adsorbed with Ca3(PO4)2 (Plasma C) (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
13.0 
0.08 
0.02 
16.0 
0.09 
0.01 
18.5 
Stored oxalated plasma (ml.) 
Plasma C treated with thrombin* (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
12.5 
0.08 
0.02 
14.5 
0.09 
0.01 
17.0 
Stored oxalated plasma (ml.) 
Stored plasma treated with thrombin* (ml.) 
Prothrombin time (sec.) 
0.07 
0.03 
48.0 
0.08 
0.02 
47.5 
0.09 
0.01 
44.0 
* Five units of thrombin were added to 1 ml. of plasma. The  
defibrinated plasma was kept at 4°C. for one hour before testing. 
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but adsorption with Ca3(PO4)2 removes this increased activity. When oxalated 
plasma is adsorbed with Ca3(PO4)2 before the addition of thrombin, no 
adventitious activity develops : likewise, in stored oxalated plasma, this 
activity fails to develop on treatment with thrombin. 
Discussion 
The observation of various investigators that in congenital deficiency of 
labile factor the other plasma constituents which influence the prothrombin 
time are normal suggests that the plasma from such patients should be ideal 
for assaying the factor. It has, however, the disadvantage of not being readily 
available. The finding that normal plasma stored at 4°C. can be reliably 
substituted makes the quantitative study of labile factor possible and easy for 
any clinical laboratory.  
The concentration of labile factor in human blood is much lower than in 
the common laboratory animals. This observation, which was made in the 
original study (Quick, 1943), has been confirmed by Murphy and Seegers 
(1948) and by Didisheim, Hattori, and Lewis (1959). The suggestion of 
Murphy and Seegers that the low level in man may "offer at least a partial 
explanation for the reported discrepancy of prothrombin values obtained by 
the one-stage and two-stage methods" is not supported experimentally. The 
concentration of labile factor in normal human plasma is not the limiting 
factor that fixes the prothrombin time (Quick, 1958). Over one-half of the 
labile factor must be lost before the prothrombin time becomes prolonged as 
is shown in this study and was earlier reported by Alexander and DeVries 
(1949). 
Confusion still exists concerning the stability and alteration of activity 
of labile factor. It was originally observed (Quick, 1943) that native chicken 
and goose plasma showed no increase of prothrombin time kept seven days 
in a refrigerator. When these plasmas were oxalated, the prothrombin time 
became markedly prolonged on storage. This suggests that the stability of 
labile factor is decreased in the absence of ionized calcium. In the present 
study it is shown that native human plasma loses little labile factor on storage 
in 48 hours, whereas the oxalated plasma does. Significantly, when 9 vol. of 
plasma is mixed with 1 vol. of 0.1M sodium citrate, the resulting mixture 
exhibits no increase in the prothrombin time; it actually shows a decrease. If, 
instead, 0.2M citrate is used, the same increase in prothrombin time is 
observed as in oxalated plasma. The difference in stability of labile factor in 
citrated and oxalated plasma was observed by Fahey, Ware, and Seegers 
(1948), but they offered no explanation. Since 0.1M sodium citrate does not 
completely depress the ionized calcium, it seems justifiable to conclude that 
the greater stability of the labile factor in the weaker citrate plasma is due to 
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ionized calcium which is not completely depressed (Hussey, Quick, Stefanini, 
Consolazio, and Sargent, 1950).  
When blood citrated with 0.1M citrate is stored in glass at 4°C., the 
prothrombin time decreases from the initial 12 sec. to about 9 sec., whereas 
no change occurs when stored in silicone. It is further observed that both the 
oxalated and citrated plasmas stored in glass have prothrombin times of 8 to 
9 sec. when excess labile factor is added, but the same plasmas kept in 
silicone-coated test-tubes retain a prothrombin time of approximately 12 sec. 
Alexander and DeVries also noted this enhanced prothrombin activity on 
storage in glass and remarked that it could not be explained. Shortly before 
this, Quick and Stefanini (1949) formulated the hypothesis that the 
prothrombin in human blood is only partly free and that a large fraction is in 
an inactive state. On storage in glass the inactive prothrombin becomes 
activated, whereupon the prothrombin time is shortened. In both oxalated 
and citrated plasma this activation readily occurs in glass but not in silicone. 
Since the rate at which labile factor decreases in oxalated and in 0.2M sodium 
citrated plasmas is much greater than the speed of activation of 
prothrombinogen, the prothrombin time steadily increases. In the plasma 
with 0.1M sodium citrate, the reverse is true because the rate with which 
labile factor disappears is much slower than that of the activation of inactive 
prothrombin. 
During storage of adult human plasma in glass at 4°C., two changes 
are occurring simultaneously: labile factor is diminishing and, according to the 
author's hypothesis, inactive prothrombin is being converted to the active 
form. The latter reaction, which is measurable by the one-stage prothrombin 
time, is masked unless the first is retarded, as occurs when plasma is mixed 
with 0.1M sodium citrate. These changes occur in the absence of thrombin. 
When oxalated plasma is treated with thrombin and incubated for one hour to 
permit inactivation of the added thrombin, the resulting defibrinated plasma 
has, when tested by our assay method, shown a marked increase in what 
appears to be labile factor activity. When, however, the defibrinated plasma is 
treated with Ca3(PO4)2, this hyperactivity is lost and the adsorbed plasma is 
found to have a slightly lower concentration of labile factor than it had before 
treatment with thrombin. This clearly suggests that thrombin brings about the 
generation of another factor which acts synergistically with labile factor to 
shorten the prothrombin time markedly. If oxalated plasma is adsorbed with 
Ca3(PO4)2 before treatment with thrombin, no hyperactivity develops. 
Likewise, thrombin fails to produce this adventitious activity in stored plasma. 
This factor which is activated by thrombin appears to be distinct and 
independent of labile factor. It is adsorbed by Ca3(PO4)2and is absent in 
stored plasma. It is probably identical with the agent Alexander, DeVries, 
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Goldstein, and Landwehr (1949) named S.P.C.A. (serum prothrombin 
conversion accelerator). 
The activation of this new factor explains the apparently high labile 
factor activity in serum. When, however, the serum is adsorbed with 
Ca3(PO4)2, it is found that the labile factor has actually diminished. The more 
complete the clotting as measured by the prothrombin consumption test, the 
greater the decrease of labile factor, and conversely in defective clotting, such 
as occurs in haemophilia and thrombocytopenia, much labile factor remains in 
the serum. This was reported by Alexander, Goldstein, and Landwehr (1950) 
and again recently by Douglas (1956). 
These observations suggest that labile factor enters the reaction as a 
reactant and not as an accelerator. At the time Fahey et al. (1948) carried out 
their studies on the factor which they called Ac-globulin, the S.P.C.A. of 
Alexander had not been recognized. The observation of greater activity in 
serum was regarded as an activation of Ac-globulin; they distinguished 
between plasma Ac-globulin and serum Ac-globulin and postulated that the 
factor existed in plasma in an inactive state, probably as a proenzyme. Owren 
(1951) has also accepted the view that the factor is in a precursor state and 
has designated it proaccelerin. As Alexander et al. (1950) pointed out, the 
activity which is called serum Ac-globulin (and one can also include Owren's 
accelerin) is in all probability a mixture of plasma Ac-globulin or labile factor 
with S.P.C.A. The hypothesis that labile factor exists in blood in a precursor 
state and that when activated it becomes an accelerator is based on 
experimental observations which require reinterpretation. 
The probable place at which labile factor enters the coagulation 
reaction was investigated by Quick and Stefanini (1950). They observed that 
little or no prothrombin consumption occurs when tissue thromboplastin 
(rabbit brain extract) is added to recalcified stored plasma, but that the 
addition of increasing amounts of labile factor to this system brought about 
corresponding increments of prothrombin consumption. This indicated that 
labile factor acts stoichiometrically and is essential in the utilization of 
extrinsic thromboplastin. Our observation that prothrombin consumption is 
very low in a patient with congenital deficiency of labile factor shows that the 
factor is also essential for the utilization of intrinsic thromboplastin. It can be 
concluded that labile factor enters at a late stage of the clotting reaction. It 
actually appears to be a thromboplastin co-factor, a term which Honorato 
(1947) suggested. Douglas (1956) has also concluded that the factor enters 
at a stage later than antihaemophilic globulin, Christmas factor, and platelets. 
This study was made possible through the kind co-operation of Dr. 
Irving Friedman, Hektoen Institute, Cook County Hospital, Chicago, Illinois. I 
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wish to thank him for the opportunity of studying his patients with severe 
labile factor deficiency. 
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